NicOx, Pfizer announce phase II trial of latanoprost derivative

NicOx and Pfizer will initiate a phase II, dose-finding study of its PF-03187207 compound for the treatment of patients with glaucoma and ocular hypertension. The 28-day trial is designed to compare the safety and efficacy of the drug with that of latanoprost (Xalatan, Pfizer Ophthalmics).

Key Points

Sophia Antipolis, France-NicOx and Pfizer will initiate a phase II, dose-finding study of its PF-03187207 compound for the treatment of patients with glaucoma and ocular hypertension.

The 28-day trial is designed to compare the safety and efficacy of the drug with that of latanoprost (Xalatan, Pfizer Ophthal mics). The trial will involve parallel groups in a randomized, double-masked study and will enroll about 150 patients with primary open-angle glaucoma in one or both eyes.

This first clinical trial will evaluate the change in diurnal IOP at day 28. Secondary endpoints will include the change in IOP from baseline at the study center visits at four points during the trial, the proportion of patients at target IOP across all study visits, and safety.